Ada Waks, Associate Director of Breast Oncology Clinical Research at Dana-Farber Cancer Institute, shared an update from Dana-Farber’s Breast Oncology Center, on X, adding:
“Excited to share the publication of our phase 1 trial for a novel triplet regimen targeting the MAPK pathway in CDK4/6i-resistant HR+ MBC! Phase 2 trial of the same regimen is enrolling now!!”
Quoting Dana-Farber’s Breast Oncology Center:
“New Clinical Cancer Research.”
Title: Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial
Authors: Adrienne G Waks, Elia Segui, Tianyu Li, Marla Lipsyc-Sharf, Eliza Kallfelz, Molly DiLullo, Ashka Patel, Tasnim Rahman, Katherine Junkins, Hajer Rahee, Anna Mae Frey, Emma Kelly, Michael Stalteri, Eileen Wrabel, Amy Williams, Heather Parsons, Philip D Poorvu, Ann Partridge, Daniel L Abravanel, Nancy Poorvu, Barbara LeStage, Piotr Sicinski, Sara M Tolaney, Nikhil Wagle, Nabihah Tayob, Geoffrey I Shapiro.
Read the full article.
This also can be interesting:
EVERGREEN Study: Everolimus Shows Modest Benefit After CDK4/6 Progression
